{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:52:14Z","timestamp":1765961534899},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CURR MED SCI"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11596-022-2587-3","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T09:02:46Z","timestamp":1654074166000},"page":"530-537","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Chemotherapy-Induced Myelosuppression in Esophageal Cancer Patients: Risks and Suggestions for Its Management"],"prefix":"10.1007","volume":"42","author":[{"given":"Qi-lin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-ming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"issue":"10125","key":"2587_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 2018,391(10125):1023\u20131075","journal-title":"Lancet (London, England)"},{"issue":"10","key":"2587_CR2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1080\/14656566.2017.1334764","volume":"18","author":"E Bollschweiler","year":"2017","unstructured":"Bollschweiler E, Plum P, Monig SP, et al. Current and future treatment options for esophageal cancer in the elderly. Expert Opin Pharmacother, 2017,18(10):1001\u20131010","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"2587_CR3","doi-asserted-by":"publisher","first-page":"S1367","DOI":"10.1016\/S0003-4975(03)01202-5","volume":"76","author":"A Pickens","year":"2003","unstructured":"Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg, 2003,76(4):S1367\u20131369","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"2587_CR4","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1002\/ijc.23232","volume":"122","author":"C Bosetti","year":"2008","unstructured":"Bosetti C, Levi F, Ferlay J, et al. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer, 2008,122(5):1118\u20131129","journal-title":"Int J Cancer"},{"issue":"suppl5","key":"2587_CR5","doi-asserted-by":"publisher","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","volume":"27","author":"F Lordick","year":"2016","unstructured":"Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann oncol, 2016,27 (suppl 5):v50\u2013v57","journal-title":"Ann oncol"},{"issue":"8","key":"2587_CR6","doi-asserted-by":"publisher","first-page":"830","DOI":"10.6004\/jnccn.2011.0072","volume":"9","author":"JA Ajani","year":"2011","unstructured":"Ajani JA, J.S. Barthel JS, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw, 2011,9(8):830\u2013887","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2587_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00595-019-01878-7","volume":"50","author":"M Watanabe","year":"2020","unstructured":"Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today, 2020,50(1):12\u201320","journal-title":"Surg Today"},{"issue":"2","key":"2587_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13402-019-00488-2","volume":"43","author":"A Fatehi Hassanabad","year":"2020","unstructured":"Fatehi Hassanabad A, Chehade R, Breadner D, et al. Esophageal carcinoma: Towards targeted therapies. Cell Oncol (Dordr), 2020,43(2):195\u2013209","journal-title":"Cell Oncol (Dordr)"},{"issue":"2","key":"2587_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cacc.2008.01.004","volume":"19","author":"C Carr","year":"2008","unstructured":"Carr C, Ng J, Wigmore T. The side effects of chemotherapeutic agents. Curr Anaesth Crit Care, 2008,19(2):70\u201379","journal-title":"Curr Anaesth Crit Care"},{"issue":"2","key":"2587_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer, 2004,100(2):228\u2013237","journal-title":"Cancer"},{"issue":"19","key":"2587_CR11","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","volume":"91","author":"JE Groopman","year":"1999","unstructured":"Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst, 1999,91(19):1616\u20131634","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2587_CR12","first-page":"282","volume":"29","author":"DJ Kuter","year":"2015","unstructured":"Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology, 2015,29(4):282\u2013294","journal-title":"Oncology"},{"issue":"5","key":"2587_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1177\/0897190014546108","volume":"27","author":"JN Barreto","year":"2014","unstructured":"Barreto JN, McCullough KB, Ice LL, et al. Antineoplastic agents and the associated myelosuppressive effects: a review. J Pharm Pract, 2014,27(5):440\u2013446","journal-title":"J Pharm Pract"},{"issue":"402","key":"2587_CR14","doi-asserted-by":"publisher","first-page":"eaa","DOI":"10.1126\/scitranslmed.aam8060","volume":"9","author":"SJ Taylor","year":"2017","unstructured":"Taylor SJ, Duyvestyn JM, Dagger SA, et al. Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. Sci Transl Med, 2017,9(402):eaam8060","journal-title":"Sci Transl Med"},{"issue":"2","key":"2587_CR15","doi-asserted-by":"publisher","first-page":"e004498","DOI":"10.1161\/JAHA.116.004498","volume":"6","author":"WJ Yin","year":"2017","unstructured":"Yin WJ, Yi YH, Guan XF, et al. Preprocedural Prediction Model for Contrast-Induced Nephropathy Patients. J Am Heart Assoc, 2017,6(2):e004498","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"2587_CR16","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1007\/s12325-020-01419-6","volume":"37","author":"RS Epstein","year":"2020","unstructured":"Epstein RS, Aapro MS, Basu Roy UK, et al. Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors. Adv Ther, 2020,37(8):3606\u20133618","journal-title":"Adv Ther"},{"key":"2587_CR17","unstructured":"Grading standard for acute and subacute toxicity of anticancer drugs (WHO standard), Cancer, 1992,(3):254"},{"key":"2587_CR18","doi-asserted-by":"publisher","first-page":"835616","DOI":"10.3389\/fphar.2022.835616","volume":"13","author":"A Saggam","year":"2022","unstructured":"Saggam A, Kale P, Shengule S, et al. Ayurveda-based Botanicals as Therapeutic Adjuvants in Paclitaxel-induced Myelosuppression. Front Pharmacol, 2022,13: 835616","journal-title":"Front Pharmacol"},{"key":"2587_CR19","doi-asserted-by":"publisher","first-page":"668140","DOI":"10.3389\/fonc.2021.668140","volume":"11","author":"Y Zheng","year":"2021","unstructured":"Zheng Y, Li Y, Liu X, et al. Multicentre Comparison of the Toxicity and Effectiveness of Lobaplatin-Based Versus Cisplatin-Based Adjuvant Chemotherapy in Oesophageal Carcinoma. Front Oncol, 2021,11:668140","journal-title":"Front Oncol"},{"issue":"8","key":"2587_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.5483\/BMBRep.2017.50.8.099","volume":"50","author":"MH Park","year":"2017","unstructured":"Park MH, Jung IK, Min WK, et al. Neuropeptide Y improves cisplatin-induced bone marrow dysfunction without blocking chemotherapeutic efficacy in a cancer mouse model. BMB reports, 2017,50(8):417\u2013422","journal-title":"BMB reports"},{"issue":"7","key":"2587_CR21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/2472555218777968","volume":"23","author":"KK Javarappa","year":"2018","unstructured":"Javarappa KK, D. Tsallos D, Heckman CA. A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow. SLAS Discov, 2018,23(7):687\u2013696","journal-title":"SLAS Discov"},{"issue":"1","key":"2587_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/cancers11010100","volume":"11","author":"CJ Reddel","year":"2019","unstructured":"Reddel CJ, Tan CW, Chen VM. Thrombin Generation and Cancer: Contributors and Consequences. Cancers, 2019,11(1):100","journal-title":"Cancers"},{"issue":"6","key":"2587_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/01.coc.0000436088.69084.22","volume":"38","author":"W Sun","year":"2015","unstructured":"Sun W, Ren H, Gao CT, et al. Clinical and Prognostic Significance of Coagulation Assays in Pancreatic Cancer Patients With Absence of Venous Thromboembolism. American J Clin Oncol, 2015,38(6):550\u2013556","journal-title":"American J Clin Oncol"},{"issue":"3","key":"2587_CR24","first-page":"216","volume":"45","author":"MB Bestari","year":"2013","unstructured":"Bestari MB, Agustanti N. Obstructive jaundice due to pancreatic metastasis from non-small cell lung cancer. Acta medica Indonesiana, 2013,45(3):216\u2013219","journal-title":"Acta medica Indonesiana"},{"issue":"3","key":"2587_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/jrr\/rrz006","volume":"60","author":"XB Wang","year":"2019","unstructured":"Wang XB, Wu DJ, Chen WP, et al. Impact of radiotherapy on immunological parameters, levels of inflammatory factors, and clinical prognosis in patients with esophageal cancer. J Radiat Res, 2019,60(3):353\u2013363","journal-title":"J Radiat Res"},{"issue":"13","key":"2587_CR26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/jnci\/djr203","volume":"103","author":"S Bhat","year":"2011","unstructured":"Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett\u2019s esophagus patients: results from a large population-based study. J Natl Cancer Inst, 2011,103(13):1049\u20131057","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2587_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.asjsur.2016.10.005","volume":"41","author":"FL Huang","year":"2018","unstructured":"Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg, 2018, 41(3):210\u2013215","journal-title":"Asian J Surg"},{"issue":"5","key":"2587_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/sj.bjc.6605246","volume":"101","author":"MB Cook","year":"2009","unstructured":"Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977\u20132005. Brit J Cancer, 2009,101(5):855\u2013859","journal-title":"Brit J Cancer"},{"issue":"9","key":"2587_CR29","first-page":"4889","volume":"35","author":"M Ohira","year":"2015","unstructured":"Ohira M, Kubo N, Yamashita Y, et al. Impact of Chemoradiation-induced Myelosuppression on Prognosis of Patients with Locally Advanced Esophageal Cancer After Chemoradiotherapy Followed by Esophagectomy. Anticancer Res, 2015,35(9):4889\u20134895","journal-title":"Anticancer Res"},{"issue":"2","key":"2587_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dote.12479","volume":"30","author":"T Ojima","year":"2017","unstructured":"Ojima T, Nakamori M, Nakamura M, et al. Phase I\/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus. Dis Esophagus, 2017,30(2):1\u20137","journal-title":"Dis Esophagus"},{"issue":"1","key":"2587_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5301\/tj.5000665","volume":"104","author":"YQ Lan","year":"2018","unstructured":"Lan YQ, Wu RP, Huang XB, et al. Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer. Tumori, 2018,104(1):22\u201329","journal-title":"Tumori"},{"key":"2587_CR32","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.biomaterials.2015.03.009","volume":"53","author":"J Liu","year":"2015","unstructured":"J. Liu, Z. Wang, Wu K, et al. Paclitaxel or 5-fluorouracil\/esophageal stent combinations as a novel approach for the treatment of esophageal cancer. Biomaterials, 2015,53:592\u2013599","journal-title":"Biomaterials"}],"container-title":["Current Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-022-2587-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11596-022-2587-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-022-2587-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T06:43:25Z","timestamp":1727333005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11596-022-2587-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["2587"],"URL":"https:\/\/doi.org\/10.1007\/s11596-022-2587-3","relation":{},"ISSN":["2096-5230","2523-899X"],"issn-type":[{"type":"print","value":"2096-5230"},{"type":"electronic","value":"2523-899X"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"5 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}